2008
DOI: 10.1093/ndt/gfp090
|View full text |Cite
|
Sign up to set email alerts
|

The improvement of renal survival with steroid pulse therapy in IgA nephropathy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
12
0

Year Published

2009
2009
2018
2018

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(12 citation statements)
references
References 0 publications
0
12
0
Order By: Relevance
“…In the early phase of inflammation, steroid pulse therapy immediately suppressed the inflammation in glomerulus. 10 Regarding steroid pulse therapy for cardiac sarcoidosis, this is the first case report in which steroid pulse therapy was effective in patient with cardiac sarcoidosis in active inflammation phase. Because cardiac sarcoidosis is a rare disease, large-scale randomized controlled trial is difficult to perform.…”
Section: Discussionmentioning
confidence: 92%
“…In the early phase of inflammation, steroid pulse therapy immediately suppressed the inflammation in glomerulus. 10 Regarding steroid pulse therapy for cardiac sarcoidosis, this is the first case report in which steroid pulse therapy was effective in patient with cardiac sarcoidosis in active inflammation phase. Because cardiac sarcoidosis is a rare disease, large-scale randomized controlled trial is difficult to perform.…”
Section: Discussionmentioning
confidence: 92%
“…Katafuchi et al. reported a glomerular score calculated as the sum of indices of the following three glomerular lesions: hypercellularity; segmental lesions including crescent, tuft necrosis, tuft adhesion, and segmental sclerosis; and global sclerosis. We defined the grade of renal injury as follows.…”
Section: Methodsmentioning
confidence: 99%
“…41,42 This is consistent with a retrospective analysis in 702 IgAN patients where corticosteroid pulse therapy as well as ACE-inhibitor therapy independently reduced progression of disease. 43 Both the trial of Manno et al and Lv et al 35,34 (Table 2) suffer from their study design, as patients were required to discontinue prior ACE inhibitor or angiotensin receptor blocker (ARB) therapy. Then, in the combination groups, they started receiving simultaneously an ACE inhibitor and corticosteroids.…”
Section: Nonestablished and Controversial Nonimmunosuppressive Treatmmentioning
confidence: 99%